Last updated: September 5, 2026
Rubidium chloride Rb-82 is a short-lived PET myocardial perfusion agent supplied through a strontium-82/rubidium-82 generator, primarily marketed as CardioGen-82 by Bracco Diagnostics. Its commercial value is tied less to the chemical compound than to generator manufacturing, radionuclide supply, quality controls, PET infrastructure, reimbursement, and protection against strontium breakthrough.
The product has a defensible but concentrated market position. FDA approval and reimbursement support established demand, while the market remains constrained by high generator costs, limited suppliers, short product life, regulatory complexity, and competition from SPECT and emerging PET agents. Public sources do not report standalone CardioGen-82 revenue, so financial analysis must rely on market drivers rather than product-level sales disclosures.
What is rubidium chloride Rb-82 used for?
Rubidium chloride Rb-82 is used for PET myocardial perfusion imaging in adults at rest and during pharmacologic stress. It measures myocardial blood flow and identifies areas of reduced perfusion associated with coronary artery disease.
Rb-82 has a physical half-life of approximately 75 seconds. The short half-life permits rapid sequential imaging but prevents conventional shipment of a finished radioactive dose. Healthcare providers generate the isotope at the imaging site from strontium-82 contained in a dedicated generator.[1]
| Attribute |
Rubidium chloride Rb-82 |
| Active radionuclide |
Rubidium-82 |
| Precursor |
Strontium-82 |
| Physical half-life |
Approximately 75 seconds |
| Principal use |
PET myocardial perfusion imaging |
| Administration |
Intravenous, generator-produced dose |
| Primary commercial product |
CardioGen-82 |
| Manufacturer |
Bracco Diagnostics |
| FDA pathway |
New drug application |
| Main clinical alternatives |
SPECT agents, N-13 ammonia, investigational F-18 agents |
| Core commercial constraint |
Generator cost and radionuclide supply |
The commercial product is therefore a system rather than a conventional vial of drug. The generator, elution system, dose calibrator, quality testing, shielding, and PET scanner are part of the economic model.
What is the FDA status of CardioGen-82?
CardioGen-82 is FDA-approved for PET myocardial perfusion imaging in adults at rest or under pharmacologic stress. The FDA-approved product is a generator system containing strontium-82 that produces rubidium chloride Rb-82 for intravenous administration.[1]
The product’s regulatory history has materially influenced its market trajectory. In 2011, the FDA issued a safety communication concerning CardioGen-82 after reports of elevated strontium-82 and strontium-85 breakthrough in eluted doses. Bracco recalled the product and suspended distribution while investigating the issue.[2]
The product later returned to the U.S. market after manufacturing and quality-control changes. The episode increased scrutiny of generator validation, breakthrough testing, operator procedures, and post-market monitoring. It also demonstrated that supply continuity is a commercial risk independent of clinical demand.
FDA regulatory milestones
| Milestone |
Commercial relevance |
| FDA approval of CardioGen-82 |
Established the generator-based Rb-82 PET category |
| 2011 FDA safety communication and recall |
Disrupted supply and damaged provider confidence |
| Subsequent manufacturing remediation |
Restored commercial availability under tighter controls |
| Ongoing FDA oversight |
Raises compliance costs and limits low-cost market entry |
When does rubidium chloride Rb-82 lose exclusivity?
The main U.S. market barriers for Rb-82 are not expected to arise from a single unexpired compound patent. Rb-82 is a naturally occurring radioisotope with a very short half-life, and the commercial product depends on a generator platform and manufacturing controls.
FDA regulatory exclusivity associated with the original approval is no longer the primary commercial barrier. Any exclusivity period tied to the original NDA would have expired years ago. The relevant protection is more likely to involve:
- Generator design and elution technology
- Strontium-82 production and purification
- Radionuclide separation processes
- Quality-control methods for radioactive breakthrough
- Manufacturing know-how
- Regulatory history and validated production capacity
- Supply agreements for enriched strontium targets and cyclotron capacity
A conventional generic applicant would need to reproduce a reliable generator system, demonstrate radionuclide purity, establish dose consistency, validate long-term shelf life, and obtain approval for the complete delivery system. That is a materially different challenge from filing an abbreviated application for a tablet or injectable small molecule.
What patents protect CardioGen-82 and the Rb-82 generator?
The commercial strength of the Rb-82 estate is primarily platform-based. A patent search limited to “rubidium chloride” would understate the relevant protection because the economically important technology is the strontium-82 generator and its operating controls.
Generator and manufacturing IP
Potentially relevant patent categories include:
- Generator-column composition and architecture
- Strontium-82 loading and retention materials
- Elution chemistry
- Reduction of strontium breakthrough
- Radionuclide purification
- Sterile fluid paths and dose-delivery systems
- Automated quality-control procedures
- Manufacturing methods for strontium-82 production
The strongest barriers may not be patents. Trade secrets, validated processes, regulatory files, supplier relationships, and manufacturing experience can be more important than an individual patent claim.
No practical market conclusion should rely on an assumption that a single active patent blocks competition. The likely competitive advantage is cumulative: regulated manufacturing, radionuclide sourcing, quality systems, installed-provider relationships, and the cost of proving equivalent performance.
How many companies supply rubidium chloride Rb-82?
The U.S. commercial market is highly concentrated. Bracco Diagnostics is the principal established supplier associated with CardioGen-82. The limited supplier base reflects the difficulty of producing strontium-82, operating a compliant generator manufacturing process, and supporting geographically distributed PET sites.
| Market participant type |
Role |
| Bracco Diagnostics |
CardioGen-82 generator and related commercial support |
| Cyclotron and isotope producers |
Potential upstream supply of strontium-82 |
| PET imaging centers |
End users and dose-generating sites |
| Hospital systems |
Buyers that evaluate capital, reimbursement, and throughput |
| SPECT radiopharmacy suppliers |
Providers of competing myocardial perfusion products |
| Emerging PET developers |
Potential future competitors using F-18 or other tracers |
The small number of suppliers increases customer dependence on manufacturing continuity. It also creates an opportunity for a second generator manufacturer if the entrant can meet FDA requirements and secure reliable strontium-82 supply.
How does the Rb-82 market compare with SPECT myocardial perfusion imaging?
SPECT remains the larger and more established myocardial perfusion imaging modality because it has a broad installed base, lower equipment requirements, and widely available technetium-99m-based agents. PET offers faster imaging, higher spatial resolution, improved attenuation correction, and the potential for myocardial blood-flow quantification.
| Factor |
Rb-82 PET |
SPECT |
| Imaging time |
Short |
Longer |
| Quantitative flow assessment |
Stronger capability |
More limited |
| Equipment cost |
Higher |
Lower |
| Radiopharmaceutical logistics |
Generator-dependent |
Broad radiopharmacy network |
| Supply concentration |
High |
Lower |
| Clinical throughput |
Potentially high |
Established |
| Capital barrier |
PET/CT required |
SPECT or SPECT/CT |
| Main commercial risk |
Generator availability |
Isotope and reimbursement pressure |
Rb-82 can gain share where hospitals already operate cardiac PET programs or seek higher throughput and quantitative flow data. Adoption is slower where providers lack PET/CT capacity or where payer reimbursement does not cover the full cost of the examination.
What drives the financial trajectory of rubidium chloride Rb-82?
CardioGen-82 revenue is driven by the number of active PET centers, generator placements, scan volume, generator utilization, reimbursement, and supply continuity. Product revenue is not normally disclosed separately by Bracco, which is privately held.
Primary growth drivers
- Expansion of cardiac PET from academic centers into community hospitals
- Greater use of myocardial blood-flow quantification
- Physician preference for shorter imaging protocols
- Growth in coronary artery disease diagnosis and risk stratification
- Increased PET/CT capacity
- Reimbursement support for cardiac PET
- Replacement of some SPECT volume in high-throughput centers
Primary constraints
- Generator acquisition and replacement cost
- Limited strontium-82 production
- Nuclear pharmacy and radiation-safety requirements
- Need for PET/CT capital investment
- Product availability risk
- Quality-control obligations
- Payer variation
- Competition from established SPECT workflows
The financial trajectory is therefore likely to be moderate and capacity-dependent rather than a rapid volume-driven pharmaceutical growth story. Revenue can increase through more generator placements and higher utilization, but the market cannot scale independently of isotope supply and PET infrastructure.
What reimbursement factors affect Rb-82 demand?
Medicare coverage for PET has supported use of PET myocardial perfusion imaging in appropriate clinical settings. CMS coverage policies address PET studies for certain cardiac indications, subject to applicable requirements and billing rules.[3]
The commercial economics depend on the spread between reimbursement and total procedure cost. Total cost includes:
- Generator acquisition or rental
- Per-dose radiopharmaceutical expense
- PET/CT depreciation
- Radiochemistry and nuclear medicine staffing
- Radiation-safety compliance
- Maintenance and service contracts
- Facility overhead
- Payer authorization and denied-claim risk
A favorable reimbursement environment can justify generator placement at centers with sufficient patient volume. A weak reimbursement environment can make SPECT economically preferable even when PET provides superior technical performance.
What generic entry risks exist for CardioGen-82?
A conventional generic launch is unlikely to follow the standard oral-solid-dose model. A competitor would need to establish a complete alternative generator platform and satisfy FDA requirements for:
- Radionuclide identity and purity
- Strontium breakthrough limits
- Sterility and endotoxin control
- Elution yield and dose consistency
- Generator shelf life
- Radiation shielding and operator safety
- Compatibility with the administration system
- Reliable commercial-scale isotope supply
The most credible entry scenario is a competing Rb-82 generator rather than a conventional generic rubidium chloride injection. That entrant would face high fixed costs, long regulatory development timelines, specialized manufacturing, and limited initial customer concentration.
The second entry path is substitution by another cardiac PET tracer. N-13 ammonia is an established PET myocardial perfusion option in the U.S., but its two-minute half-life requires nearby cyclotron access. F-18-labeled agents, including flurpiridaz, could reduce the logistics limitations associated with short-lived isotopes if approved and commercially scaled. As of the latest widely available FDA status, flurpiridaz remained an investigational product rather than an approved commercial competitor.[4]
Which companies are challenging the Rb-82 market?
The principal competitive pressure comes from modalities and tracer platforms rather than from multiple direct Rb-82 manufacturers.
Direct competition
A direct competitor would need to commercialize another FDA-approved Sr-82/Rb-82 generator. The market has not developed a broad field of equivalent U.S. suppliers.
Indirect competition
- GE HealthCare and other suppliers of PET/CT systems
- Nuclear medicine companies supplying SPECT agents
- Producers of N-13 ammonia
- Developers of F-18 myocardial perfusion tracers
- Hospital-owned cyclotron networks
- Imaging providers using advanced SPECT/CT protocols
The competitive contest is based on total cost per diagnostic study, throughput, quantitative capability, supply reliability, and payer coverage.
What patent litigation and Paragraph IV activity affect Rb-82?
There is no widely reported, market-defining Paragraph IV campaign comparable to those involving major oral drugs or biologics. The product’s generator-based structure, specialized manufacturing, and concentrated supply chain reduce the likelihood of a conventional ANDA dispute.
Patent litigation risk could arise around generator architecture, radionuclide separation, breakthrough-control methods, or manufacturing equipment. Regulatory litigation and product-liability exposure may be more commercially important than classic Orange Book litigation because radioactive contamination and dose-purity failures can create immediate operational and patient-safety consequences.
The absence of a visible Paragraph IV contest does not eliminate entry risk. It indicates that technical and regulatory execution are likely more important than a simple challenge to a listed drug patent.
What is the commercial outlook for rubidium chloride Rb-82?
The base case is a stable-to-growing niche market with moderate expansion in cardiac PET. Demand should benefit from broader PET adoption and clinical interest in myocardial blood-flow quantification. Growth will remain constrained by generator supply, cost, and hospital capital requirements.
Base-case trajectory
| Period |
Expected market pattern |
| Near term |
Stable demand from established cardiac PET centers |
| Medium term |
Gradual growth from new PET installations and higher utilization |
| Longer term |
Increased competitive pressure from F-18 PET agents if approved |
| Downside scenario |
Generator disruption, reimbursement reduction, or safety event |
| Upside scenario |
Broader cardiac PET coverage and community-hospital adoption |
Revenue exposure is concentrated in the product supplier and in upstream isotope production. A manufacturing interruption can produce a disproportionate financial impact because providers may have limited immediate alternatives.
Key Takeaways
- Rubidium chloride Rb-82 is a generator-produced PET myocardial perfusion agent, not a conventional injectable supplied from a central pharmacy.
- CardioGen-82 is the principal established U.S. commercial product associated with Rb-82.
- The product’s commercial moat depends on generator technology, isotope supply, validated manufacturing, quality systems, and regulatory execution.
- Original regulatory exclusivity is no longer the main barrier to competition.
- No broad Paragraph IV challenge has defined the market.
- Direct generic competition would require a complete alternative Sr-82/Rb-82 generator platform.
- SPECT remains the primary commercial competitor because of its lower infrastructure requirements.
- Cardiac PET expansion, reimbursement, scanner availability, and quantitative flow assessment support demand.
- Strontium-82 supply, generator reliability, and the 2011 safety history remain material market risks.
- F-18 myocardial perfusion tracers could become the most important future competitive threat if they achieve FDA approval and commercial scale.
FAQs
Is rubidium chloride Rb-82 a generic drug?
No. Rb-82 is a radioactive medicinal product generated from strontium-82. The commercial product includes a specialized generator and controlled elution system.
How long does a CardioGen-82 generator last?
The generator has a limited labeled operating life determined by radioactive decay, product design, and manufacturer specifications. Its economic life is shorter than that of conventional pharmaceutical manufacturing equipment.
Can Rb-82 be shipped to hospitals as a finished dose?
No. Its approximately 75-second half-life requires production at or near the imaging site through a strontium-82 generator.
Is CardioGen-82 listed in the Orange Book?
The relevant competitive assessment cannot be reduced to a conventional Orange Book patent listing. The principal barriers involve the generator, manufacturing process, isotope supply, and regulatory controls.
What drug could replace Rb-82 PET?
Potential substitutes include N-13 ammonia, SPECT myocardial perfusion agents, and future F-18 myocardial perfusion tracers. Each has different requirements for isotope production, imaging infrastructure, reimbursement, and distribution.
References
-
U.S. Food and Drug Administration. (n.d.). CardioGen-82 (rubidium Rb 82 chloride injection) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2011). FDA drug safety communication: Important safety information for CardioGen-82. FDA.
-
Centers for Medicare & Medicaid Services. (n.d.). National Coverage Determination 220.6: PET scans. CMS.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs and investigational drug development records. FDA.
-
Society of Nuclear Medicine and Molecular Imaging. (2018). Appropriate use criteria for myocardial perfusion imaging. SNMMI.
